Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678505 | 1.00 | BACE1 (0.36) | BACE1ADRB2ADRB3ADRB1GLA | |
| SCHEMBL6682398 | 0.93 | ADRB3 (0.38) | BACE1ADRB2ADRB3ADRB1CYP3A4 | |
| SCHEMBL6682392 | 0.93 | ADRB3 (0.38) | BACE1ADRB2ADRB3ADRB1CYP3A4 | |
| SCHEMBL6803604 | 0.84 | BACE1 (0.35) | BACE1ADRB2ADRB3ADRB1GLA | |
| SCHEMBL6803923 | 0.84 | BACE1 (0.35) | BACE1ADRB2ADRB3ADRB1GLA | |
| SCHEMBL6539495 | 0.83 | ADRB3 (0.40) | BACE1ADRB2ADRB3ADRB1GLA | |
| SCHEMBL6539501 | 0.83 | ADRB3 (0.40) | BACE1ADRB2ADRB3ADRB1GLA | |
| SCHEMBL6803924 | 0.82 | BACE1 (0.36) | BACE1ADRB2ADRB3ADRB1GLA | |
| SCHEMBL6803607 | 0.82 | BACE1 (0.36) | BACE1ADRB2ADRB3ADRB1GLA | |
| SCHEMBL6803605 | 0.82 | BACE1 (0.36) | BACE1ADRB2ADRB3ADRB1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | BACE1 4413/4885ADRB2 30/4885ADRB3 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.